Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak
Closed Special Notice Posted
- Solicitation number
- OC-2026-135667
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Liverpool United Kingdom
Notice details come from SAM.gov. Updated .
About this opportunity
The Food and Drug Administration issued a Notice of Intent to Award a Sole Source contract to The University of Liverpool for sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, with responses due by 5:00 pm July 29, 2026. This is a firm-fixed-price purchase order under simplified acquisition procedures (FAR Part 12), justified under the sole-source authority of FAR 6.103-1 (Only One Responsible Source). The procurement falls under NAICS 541714 (Research and Development in Biotechnology). The primary objective is to obtain critical reagents—reference standards and internal standards—to support bioanalytical method development and sample analysis for quantification of CYP enzyme substrates, metabolites, and transporter substrates in hepatocyte experiments. Any firm other than the named awardee wishing consideration must submit a capability statement to Ryan Alexander (ryan.alexander@fda.hhs.gov) by the deadline. The Government will review all responses to determine capability to meet requirements, and the final decision to compete or proceed as sole source rests solely with the Government.
Notice text
Procurement Type: Sole Source Simplified Acquisition Procedures (SAP) Purchase Order for Commercial Items
Authority: FAR Part 6.103-1, Only One Responsible Source
Subject: Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak
Description: The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, in accordance with the authority under FAR Part 6.103-1, Only One Responsible Source. This procurement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).
The primary objective of this requirement is to obtain critical reagents such as procure reference standards and internal standards to perform bioanalytical method development and sample analysis to determine the quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments.
Responses:
Responses to this notice should be sent to Ryan Alexander at ryan.alexander@fda.hhs.gov by 5:00 pm July 29, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity